Safety and efficacy of trastuzumab biosimilar plus irinotecan or gemcitabine in patients with previously treated HER2 (ERBB2)-positive non-breast/non-gastric solid tumors: a phase II basket trial with circulating tumor DNA analysis

Omar, 2015, HER2: an emerging biomarker in non-breast and non-gastric cancers, Pathogenesis, 2, 1, 10.1016/j.pathog.2015.05.002 Bang, 2010, Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial, Lancet, 376, 687, 10.1016/S0140-6736(10)61121-X Slamon, 2001, Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2, N Engl J Med, 344, 783, 10.1056/NEJM200103153441101 Verma, 2012, Trastuzumab emtansine for HER2-positive advanced breast cancer, N Engl J Med, 367, 1783, 10.1056/NEJMoa1209124 Swain, 2020, Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study, Lancet Oncol, 21, 519, 10.1016/S1470-2045(19)30863-0 Hainsworth, 2018, Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from MyPathway, an open-label, phase IIa multiple basket study, J Clin Oncol, 36, 536, 10.1200/JCO.2017.75.3780 Wan, 2017, Liquid biopsies come of age: towards implementation of circulating tumour DNA, Nat Rev Cancer, 17, 223, 10.1038/nrc.2017.7 Ignatiadis, 2021, Liquid biopsy enters the clinic - implementation issues and future challenges, Nat Rev Clin Oncol, 18, 297, 10.1038/s41571-020-00457-x Diehl, 2008, Circulating mutant DNA to assess tumor dynamics, Nat Med, 14, 985, 10.1038/nm.1789 Woodhouse, 2020, Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin, PLoS One, 15, 10.1371/journal.pone.0237802 Kim, 2017, Prospective feasibility study for using cell-free circulating tumor DNA–guided therapy in refractory metastatic solid cancers: an interim analysis, JCO Precis Oncol, 1, 1, 10.1200/PO.16.00059 Pivot, 2016, A randomized phase I pharmacokinetic study comparing biosimilar candidate SB3 and trastuzumab in healthy male subjects, Clin Ther, 38, 1665, 10.1016/j.clinthera.2016.06.002 Pivot, 2018, J Clin Oncol, 36, 968, 10.1200/JCO.2017.74.0126 Khiabanian, 2018, Inference of germline mutational status and evaluation of loss of heterozygosity in high-depth, tumor-only sequencing data, JCO Precis Oncol, 1, 10.1200/PO.17.00148 Meric-Bernstam, 2019, Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study, Lancet Oncol, 20, 518, 10.1016/S1470-2045(18)30904-5 Sartore-Bianchi, 2016, Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial, Lancet Oncol, 17, 738, 10.1016/S1470-2045(16)00150-9 Javle, 2021, Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study, Lancet Oncol, 22, 1290, 10.1016/S1470-2045(21)00336-3 Oh, 2022, Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study, Lancet Gastroenterol Hepatol, 7, 522, 10.1016/S2468-1253(22)00043-7 Lamarca, 2021, Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial, Lancet Oncol, 22, 690, 10.1016/S1470-2045(21)00027-9 Yoo, 2021, Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study, Lancet Oncol, 22, 1560, 10.1016/S1470-2045(21)00486-1 Valle, 2021, Biliary tract cancer, Lancet, 397, 428, 10.1016/S0140-6736(21)00153-7 Gao, 2017, Circulating tumor DNA functions as an alternative for tissue to overcome tumor heterogeneity in advanced gastric cancer, Cancer Sci, 108, 1881, 10.1111/cas.13314 Siravegna, 2019, Plasma HER2 (ERBB2) copy number predicts response to HER2-targeted therapy in metastatic colorectal cancer, Clin Cancer Res, 25, 3046, 10.1158/1078-0432.CCR-18-3389 Nakamura, 2021, Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial, Nat Med, 27, 1899, 10.1038/s41591-021-01553-w Wang, 2019, Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer, Gut, 68, 1152, 10.1136/gutjnl-2018-316522 Yarlagadda, 2019, Trastuzumab and pertuzumab in circulating tumor DNA ERBB2-amplified HER2-positive refractory cholangiocarcinoma, NPJ Precis Oncol, 3, 19, 10.1038/s41698-019-0091-4 Shitara, 2020, Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer, N Engl J Med, 382, 2419, 10.1056/NEJMoa2004413 Yoshino, 2022, Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): final results from a phase 2, multicenter, open-label study (DESTINY-CRC01), J Clin Oncol, 40, 119, 10.1200/JCO.2022.40.4_suppl.119 Cortés J, 2022, Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer, N Engl J Med, 386, 1143, 10.1056/NEJMoa2115022 Modi, 2022, Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer, N Engl J Med, 387, 9, 10.1056/NEJMoa2203690